Status: Not yet recruiting
To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).
This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS). JadiCells are administered intravenously and are intended to modulate inflammatory responses and promote tissue repair in injured lung tissue.
Participants needed: 128
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Breathe Biologics, Inc.Updated: Mar 19, 2026
Eligibility criteria
Patients currently hospitalized [+7]
Greater than 96 h since hospitalization at the time of enrollment [+15]